Azvudine vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Azvudine · FNC
Marketed by Henan Genuine Biotech
NCT04303598 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Reported efficacy
Evaluation of azivudine tablet (FNC) combined with reverse transcriptase inhibitor therapy without anti-hiv treatment. (At 48 weeks); Preliminary evaluation of the efficacy of azivudine tablets (FNC) combined with reverse transcriptase inhibitors in the treatment of patients who have not received anti-hiv treatment. (At 48 weeks): 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) (unclear)
Result source: NCT04109183
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
Reported efficacy
Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)
Result source: NCT00254046
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Azvudine | Etravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | 56% vs 39%a+17 vs placeboNCT00254046 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not posted · NCT00255099 |
| CD4 count, change (week 48) | —Not reported | —Not posted · NCT00255099 |
HIV-1 RNA below 50 copies/mL (week 48)
- Azvudine
- —Not reported
- Etravirine
- 56% vs 39%a+17 vs placeboNCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)
- Azvudine
- —Not reported
- Etravirine
- —Not posted · NCT00255099
CD4 count, change (week 48)
- Azvudine
- —Not reported
- Etravirine
- —Not posted · NCT00255099
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Azvudine: 0 of 4 rows · Etravirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Etravirine |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results20.3%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 36%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 40%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 24.8% NCT00665847 · Phase 2 · registry result, not featured evidence 20.3% NCT00903682 · Phase 2 · registry result, not featured evidence 34.1% NCT00128830 · Phase 2 · registry result, not featured evidence 5%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.7%a NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results3.8%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 4%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 8%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00665847 · Phase 2 · registry result, not featured evidence 7.6% NCT00903682 · Phase 2 · registry result, not featured evidence 4.7% NCT00128830 · Phase 2 · registry result, not featured evidence —Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence —Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence — NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 10%a NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results15.2%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 8%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 16%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 5% NCT00665847 · Phase 2 · registry result, not featured evidence 13.9% NCT00903682 · Phase 2 · registry result, not featured evidence 21.8% NCT00128830 · Phase 2 · registry result, not featured evidence 25%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 50%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence 0%200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0%200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination 20% NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | a cough 2.8% upper respiratory tract infection 2.8% pregnancy 2.2% NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results400 mg once daily elevated level of transaminase 11.4% hyperbilirubinemia 7.6% hyperlipidemia 7.6% NCT00959894 · Phase 2 · registry result, not featured evidence 400/100 mg cough 16% headache 12% influenza 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination 300/100 mg cough 20% nausea 16% blood bilirubin increased 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 26.7% diarrhoea 15.8% cough 12.9% NCT00665847 · Phase 2 · registry result, not featured evidence nasopharyngitis 21.5% headache 16.5% diarrhoea 10.1% NCT00903682 · Phase 2 · registry result, not featured evidence diarrhoea 17.5% upper respiratory tract infection 17.1% sinusitis 11.4% NCT00128830 · Phase 2 · registry result, not featured evidence blood bicarbonate decreased 90% blood sodium decreased 70% nasal congestion 70% NCT01504841 · Phase 1/2 · registry result, not featured evidence cough 100% nasal congestion 100% rhinorrhoea 100% NCT01504841 · Phase 1/2 · registry result, not featured evidence 200 mg + 200 mg headache 18.8% toothache 12.5% diarrhoea 6.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination 200 mg + 600/100 mg + 200 mg rash maculo-papular 20% scleral hyperaemia 20% headache 13.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination headache 14.3% constipation 10.7% diarrhea 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence breast tenderness 66.7% diarrhea 11.1% headache 11.1% NCT01625169 · Phase na · registry result, not featured evidence · combination altered taste 64% headache 16% rash 16% NCT01427504 · Phase na · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Etravirine
show 2 more results
show 2 more results
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azvudine's landscape · Etravirine's landscape